Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Athira Pharma, Inc. - Common Stock (NQ:ATHA)

6.580 -0.380 (-5.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying ↗
US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
News headline image
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Outlines Possible Comeback For Alzheimer's Candidate ↗
 
Via Benzinga
News headline image
Athira Pharma: Q2 Earnings Insights ↗
  Athira Pharma (NASDAQ:ATHA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
4 Analysts Have This to Say About Athira Pharma ↗
Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter: 
Via Benzinga
News headline image
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Present at Stifel 2022 Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
Data supports neuroprotective and disease modifying potential in models of Parkinson’s disease and diabetic neuropathy 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Shares Fall To 52-Week Low - Read Why ↗
 
Via Benzinga
News headline image
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗
Upgrades 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday: Alcoa, Travelers And More ↗
Morgan Stanley cut Westinghouse Air Brake Technologies Corporation (NYSE: WAB) price target from $113 to $94. Westinghouse Air Brake Technologies shares fell 1.7% to $82.36 in pre-market trading. 
Via Benzinga
News headline image
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More ↗
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
News headline image
Dow Jumps 150 Points; Ocean Bio-Chem Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday. 
Via Benzinga
News headline image
Stocks Quietly Higher as Market Attempts to Extend Rally ↗
Stocks are modestly higher at midday. 
Via Talk Markets
News headline image
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet ↗
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 30 points on Wednesday. 
Via Benzinga
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
News headline image
Exela Technologies (XELA) Stock Soars After Securing $136 Million Contract ↗
Exela Technologies (XELA) stock is taking off on Wednesday after gaining a new $136 million customer contract that lasts for three years. 
Via InvestorPlace
News headline image
Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results ↗
Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Athira Pharma Stock Is Plunging ↗
Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate... 
Via Benzinga
News headline image
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022 ↗
Upgrades 
Via Benzinga
News headline image
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
ATHIRA PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2022 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.